374 related articles for article (PubMed ID: 19558486)
21. Olanzapine: a review of rapid and long-acting parenteral formulations.
Owen RT
Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
[TBL] [Abstract][Full Text] [Related]
22. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.
Lindborg SR; Beasley CM; Alaka K; Taylor CC
Psychiatry Res; 2003 Jul; 119(1-2):113-23. PubMed ID: 12860365
[TBL] [Abstract][Full Text] [Related]
23. Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study.
Freeman DJ; DiPaula BA; Love RC
Pharmacotherapy; 2009 Aug; 29(8):930-6. PubMed ID: 19637946
[TBL] [Abstract][Full Text] [Related]
24. [New formulations of olanzapine in the treatment of acute agitation].
Bartkó G
Neuropsychopharmacol Hung; 2006 Dec; 8(4):171-8. PubMed ID: 17211052
[TBL] [Abstract][Full Text] [Related]
25. A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.
MacDonald K; Wilson M; Minassian A; Vilke GM; Becker O; Tallian K; Cobb P; Perez R; Galangue B; Feifel D
J Clin Psychopharmacol; 2012 Jun; 32(3):317-22. PubMed ID: 22544013
[TBL] [Abstract][Full Text] [Related]
26. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
Atkins S; Detke HC; McDonnell DP; Case MG; Wang S
BMC Psychiatry; 2014 Jan; 14():7. PubMed ID: 24423017
[TBL] [Abstract][Full Text] [Related]
27. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
Hill AL; Sun B; McDonnell DP
Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
San L; Estrada G; Oudovenko N; Vieta E
BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.
Meehan K; Zhang F; David S; Tohen M; Janicak P; Small J; Koch M; Rizk R; Walker D; Tran P; Breier A
J Clin Psychopharmacol; 2001 Aug; 21(4):389-97. PubMed ID: 11476123
[TBL] [Abstract][Full Text] [Related]
30. Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa.
Okasha TA; Kucukalić A; Nasr AA; Zelman M; Karamustafalioğlu O; Sir A; Harrison G; Treuer T
Curr Med Res Opin; 2009 Aug; 25(8):1889-900. PubMed ID: 19538106
[TBL] [Abstract][Full Text] [Related]
31. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
[TBL] [Abstract][Full Text] [Related]
32. Olanzapine pamoate for the treatment of schizophrenia.
Naber D
Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
[TBL] [Abstract][Full Text] [Related]
33. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
34. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
35. Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients.
Wilson MP; MacDonald K; Vilke GM; Feifel D
J Emerg Med; 2012 Nov; 43(5):889-96. PubMed ID: 20542400
[TBL] [Abstract][Full Text] [Related]
36. Intramuscular aripiprazole in the control of agitation.
Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
[TBL] [Abstract][Full Text] [Related]
37. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.
Mitchell M; Riesenberg R; Bari MA; Marquez E; Kurtz D; Falk D; Hardy T; Taylor CC; Mitchell CP; Cavazzoni P
Clin Ther; 2006 Jun; 28(6):881-92. PubMed ID: 16860171
[TBL] [Abstract][Full Text] [Related]
38. Acute dystonia with intramuscular olanzapine in adolescent mania: a report.
Goyal N; Thakur A; Sinha VK
Aust N Z J Psychiatry; 2005; 39(11-12):1046-7. PubMed ID: 16343308
[No Abstract] [Full Text] [Related]
39. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Zhornitsky S; Brunelle S; Stip E
Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
